Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)

Market Cap	12.01B +133.4%
Revenue (ttm)	5.94B +28.1%
Net Income	2.49B -29.8%
EPS	31.33 -47.8%
Shares Out	86.71M
PE Ratio	4.42
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	394,508
Average Volume	1,698,262
Open	138.64
Previous Close	138.16
Day's Range	136.31 - 141.48
52-Week Range	70.71 - 156.80
Beta	0.60
RSI	48.40
Earnings Date	May 26, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 1,246
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INDSWFTLAB

Financial Performance

In fiscal year 2025, Ind-Swift Laboratories's revenue was 5.62 billion, a decrease of -67.13% compared to the previous year's 17.09 billion. Earnings were 2.50 billion, a decrease of -53.51%.